Loading

Annals of Vascular Medicine and Research

Percutaneous Angioplasty of Juxta-Anastomotic Stenosis of Failing Distal Radio-Cephalic Hemodialytic Arteriovenous Fistulas: Our Techniques in Comparison, an Attempt to Standardize the

Research Article | Open Access | Volume 4 | Issue 1

  • 1. Department of Radiology and Interventional Radiology, “Cannizzaro” Hospital, Italy
  • 2. Departement of Nephrology and Dialysis, “Cannizzaro” Hospital, Italy
  • 3. Department of Radiology and Interventional Radiology, “S. Elia” Hospital, Italy
  • 4. IBFM, CNR, Department of Medical Physics, “Cannizzaro” Hospital, Italy
+ Show More - Show Less
Corresponding Authors
Stefania Giuffrida, Department of Radiology and Interventional Radiology, “Cannizzaro” Hospital, V. Messina 829, 95126, Catania, Italy Tel: 393286719891; Fax: 390957264577;
Abstract

Purpose: Juxta-anastomotic area is the critical zone of the distal radio-cephalic fistula for higher frequency of presentation of lesion and lower patency rates versus non-juxta-anastomotic stenosis. Our purpose was to describe our techniques for the treatment of juxta-anastomotic stenosis of failing distal radiocephalic shunt and evaluate the effectiveness of venous and anastomotic Percutaneous Transluminal Angioplasty (PTA) compared to venous PTA alone of this region.

Materials and methods: We retrospectively reviewed 175 patients with distal radio-cephalic arteriovenous fistulas (AVFs) with Echo-Color-Doppler (ECD) evidence of venous stenosis of the juxta-anastomotic region without any dynamically significant anastomosis stenosis, treated between 2008 and 2011, having at least 1-year follow-up.

Two groups were recognized: 1) 103 patients treated with venous juxta-anastomotic and anastomosis PTA (“V configuration PTA”); 2) 72 patients treated only with venous PTA (“Z o V2 configuration PTA”). Surviving Times and Primary patency at 6 and 12 months were evaluated for both groups.

Results: The immediate post-procedural technical and clinical success was 100% for all the patients. Patients treated with “V configuration PTA” – group 1showed higher survival rate free of target lesion reintervention compared to patients who underwent “Z or V2 configuration PTA”- group 2, with a statistically significant difference (P-value=0.0001) in Surviving Time. PP at 6 and 12 months were respectively 97% and 79.6% in the group 1 and 79.8% and 54.1% in the group 2.

Conclusions: We always treat venous juxta-anastomotic stenosis of distal radio-cephalic hemodialytic AVFs with PTA of the whole iuxta-anastomotic region in presence or not of dynamically significant stenosis at anastomosis.

Keywords

Arterio-venous fistula; PTA; Anastomosis; Technique; Patency

Citation

Giuffrida S, Bisceglie P, Morale W, Malfa P, Calcara G, et al. (2017) Percutaneous Angioplasty of Juxta-Anastomotic Stenosis of Failing Distal Radio-Cephalic Hemodialytic Arteriovenous Fistulas: Our Techniques in Comparison, an Attempt to Standardize the “Optimal Technique”. Ann Vasc Med Res 4(1): 1048.

ABBREVIATIONS

PTA: Percutaneous Transluminal Angioplasty; AVF: ArterioVenous Fistula; ECD: Echo-Color-Doppler; PP: Primary Patency; SP: Secondary Patency

INTRODUCTION

The number of patients who undergo hemodialysis will increase in the future for the progressively ageing population and the high incidence of diabetes. End stage renal disease (ESRD) is a very common condition: 65000 new patients undergo hemodialysis in Europe and more than 350.000 in United States with an estimated growth of up to 500.000 in 2020 [1].

The rate of failure of native, arteriovenous fistula (AVF) is still very high; most dysfunctions of the shunt are caused by stenosis of the dialytic circuit that can lead to thrombosis and loss of vascular access [2]. As it is well known, stenotic lesions of distal radio-cephalic arteriovenous shunts occur mainly in the anastomotic site in up to 64% of cases [2-6].

The juxta-anastomotic area is the region within 3 cm of the arteriovenous anastomosis [7] and it is the critical zone of the distal radio-cephalic fistula for higher frequency of presentation of lesions and lower patency rates after percutaneous transluminal angioplasty (PTA) in comparison with PTA of non juxta-anastomotic stenosis.

Reviewing the literature, we noticed that there are no authors describing in detail the exact technique to perform an effective angioplasty. Therefore, we decided to review angioplasties of distal radio-cephalic AVFs performed at our hospital, in order to understand in which way the different techniques we have used can affect the effectiveness of the treatment and to try to standardize “the optimal PTA technique”. To be effective a balloon catheter has to tear the intimal layer as well as the internal elastic lamina and at least parts of the tunica media in order to prevent elastic recoil of a stenotic vasal segment. As a response of this vascular trauma a cascade of biological reactions is initiated to repair the injured wall structures with possible, consecutive formation of neo-intimal hyperplasia [8]. We evaluated if the treatment of a non stenotic, “well-functioning” anastomosis, in association with venous PTA, in case of hemodynamically significant venous, juxta-anastomotic stenosis, is recommendable to improve primary and secondary patency.

We think that the juxta-anastomotic area has to be considered a single compartment to be treated in its entirety with angioplasty to be always performed crossing the anastomosis with the guidewire and inflation of balloon in “V shape configuration”, as it will be described below. We believe in fact that anastomosis is always involved in the dysfunctional dialytic access due to juxta-anastomotic stenosis also without or not so obvious ECD appearance.

Therefore, the purpose of our study was to describe our different PTA techniques for the treatment of distal radiocephalic hemodialytic arterio-venous shunt and evaluate the effectiveness of venous and anastomotic PTA compared with venous PTA alone.

MATERIALS AND METHODS

The IRB of the participating institution does not require approval for the type of research we performed: observational, retrospective, historical cohorts study.

All the principles of the Declaration of Helsinki were followed.

We retrospectively reviewed 298 patients with AVF, treated at our hospital between 2008 and 2011: 175 patients were assessed for eligibility and 123 patients, not meeting inclusion criteria, were excluded.

The eligibility criteria were the presence of a native, distal radio-cephalic hemodialytic fistula with clinical signs of failing dialysis access, Echo-Color-Doppler (ECD) evidence of venous juxta-anastomotic stenosis without any dynamically significant anastomotic stenosis and any other stenotic lesion of inflow or outflow, confirmed with phlebography of the upper arm, completed with cavography, having, at least, one year follow up.

After the evaluation of the eligible 175 patients, we recognized two groups in this sample: 1) 103 patients with venous juxtaanastomotic stenosis treated with venous and anastomosis’s PTA (“V configuration PTA”); 2) 72 patients with venous juxtaanastomotic stenosis treated with simple venous site PTA (“Z configuration or V2-configuration PTA”); all cases in absence of hemodynamically significant anastomosis, inflow and outflow stenosis at ECD, as required in the eligibility criteria.

When clinical and physiological indicators demonstrated that the fistula was going to fail we always performed and ECD and the treatment was always performed as soon as we found hemodynamically significant venous juxta-anastomotic stenoses.

All AVFs were always minutely studied in advance with ECD, in order to show the localization and cause of the dysfunction (stenosis, thrombotic occlusion), to evaluate the degree of stenosis, the venous outflow and the conditions of all arteries of the upper arm, to map the AVF, to measure vessel diameters, to plan the treatment and to choose the best site to perform the ultrasound-guided percutaneous access.

Treatment was most of times performed with retrograde access in venous outflow, always under ultrasound guidance, placement of 5 to 6 introducer sheaths (Radiofocus® Introducer II, Terumo, Tokio, Japan; Prelude PRO™ Merit Medical), intravenous administration of 2500 units of heparin, to avoid thrombotic events, and selective digital subtraction angiography to outline the anatomy of AVF and evaluate the lesions already studied with ultrasound. Every preliminary study was completed with phlebography of the upper arm and cavography, which always confirmed the results of ECD about the absence of other outflow stenosis.

In the group 1 (175 patients, 59% of the whole sample) balloon was delivered and inflated according to the “V shape” configuration (Figure 1a).

Figure 1a V shape configuration-group 1, venous juxta-anastomotic  stenosis and anastomosis were crossed with coaxial technique with  4 or 5 F, angled catheter and thin guidewire (0.014’) which was  retrogradely advanced into the proximal radial artery; the balloon  catheter was then passed over the guidewire and advanced to the  most central lesion and inflated at the level of the venous’s stenosis  and anastomosis for atleast 2 minutes.

Figure 1a: V shape configuration-group 1, venous juxta-anastomotic stenosis and anastomosis were crossed with coaxial technique with 4 or 5 F, angled catheter and thin guidewire (0.014’) which was retrogradely advanced into the proximal radial artery; the balloon catheter was then passed over the guidewire and advanced to the most central lesion and inflated at the level of the venous’s stenosis and anastomosis for atleast 2 minutes.

This means that juxta-anastomotic stenosis and anastomosis were crossed with coaxial technique with 4 F, angled catheter and thin guidewire (0.014”), which was retrogradely advanced into the proximal radial artery. The balloon catheter was then passed over the guidewire and inflated in the entire iuxta-anastomotic region for at least 2 minutes.

When the guidewire did not advance in the artery from the venous retrograde approach, we performed an arterial antegrade access with micro-puncture system (Micropuncture® Access Set, Cook Medical), and we crossed anastomosis and venous stenosis with a guidewire antegradely advanced in the venous outflow, this guide was pulled back and snared inside the introducer sheat previously placed in the venous retrograde access, recovered from this site and the treatment was performed from the venous approach. Even when the arterial access is required we always prefer to recover the guide from the artery to the vein and carry out the angioplasty from the venous access where usually a bigger introducer sheat is placed.

In the group 2 (72 patients, 41% of the whole sample) we crossed anastomosis with 0.014” guidewire that was retrogradely advanced in the proximal radial artery, in “V shape” configuration (Figure 1b),

Figure 1b V shape configuration-group 2, venous juxta-anastomotic  stenosis and anastomosis were crossed with the same technique  described in fig.1a, but the balloon was delivered and inflated only  on the venous juxta-anastomtic stenosis; without any dilation of the  anastomosis.

Figure 1b: V shape configuration-group 2, venous juxta-anastomotic stenosis and anastomosis were crossed with the same technique described in fig.1a, but the balloon was delivered and inflated only on the venous juxta-anastomtic stenosis; without any dilation of the anastomosis.

exactly as described before, in this case called as “V2 configuration”, or antegradely advanced in the distal radial artery, in “Z shape” configuration (Figure 1c).

Figure 1c Z shape configuration-group 2, venous juxta-anastomotic  stenosis and anastomosis were crossed with thin guidewire (0.014”)  which was antegradely advanced in the distal radial artery, in “Z  shape” configuration (Figure 1c); in any case in the group 2 the  balloon was delivered and inflated and inflated only on the venous  juxta-anastomotic stenosis; without any dilation of the anastomosis.

Figure 1c: Z shape configuration-group 2, venous juxta-anastomotic stenosis and anastomosis were crossed with thin guidewire (0.014”) which was antegradely advanced in the distal radial artery, in “Z shape” configuration (Figure 1c); in any case in the group 2 the balloon was delivered and inflated and inflated only on the venous juxta-anastomotic stenosis; without any dilation of the anastomosis.

In any case, in the group 2 the balloon was delivered and inflated only on the venous part of juxta-anastomotic region without any dilation of the anastomosis.

Venous juxta-anastomotic stenosis’s PTA was always performed, in both groups, with balloons of suitable diameter, never undersized. We usually used 3-3.5-4 mm, low profile, and compliant PTA dilatation catheters for the whole juxta-anastomotic region in the group 1 and only for the venous juxtaanastomotic region for the group 2. Multiple inflations were used for resistant lesions, using growing PTA balloons, inflated for 2 minutes at least to avoid elastic recoil.

The two groups of patients did not show any other arterial or venous stenosis except the juxta-anastomotic lesion, but in our daily practice, in presence of simultaneous non juxta-anastomotic outflow lesions we usually use suitable size standard balloons or, when this is not enough to achieve optimal results, high-pressure balloons, cutting balloons or scoring balloons.

All AVFs of the two groups were matured; matured fistulas were defined, with the “Rule of six”, as AVF with venous diameter ≥ 6 mm, blood flow rate ≥ 600 ml/min and skin depth < 6 mm, evaluated with ultrasound 6 weeks after the creation of the dialytic circuit. All AVFs were correctly used for dialysis at least two months. Both of these groups were homogeneous samples, with similar patient’s characteristics: mean age 71 years in the group 1 and 69 in the group 2; male gender 80% in the group 1 and 83.7% in the group 2; hypertension 50% in the group 1 and 59.3% in the group 2; hyperlipidemia 42% in the group 1 and 26.7% in the group 2; diabetes mellitus 57% in the group 1 and 69.8% in the group 2; AVF mean age 25 months in the group 1 and 22 months in the group 2; all patients of both groups had matured, distal, radio-cephalic fistulas, with “de novo” venous, juxta-anastomotic stenosis (Table 1).

Table 1: Baseline and procedures.

Baseline and procedures

VEN+ANAST PTA

VENOUS PTA

Nr of Patients

103

72

Mean age

71 ± 13 years

69 ± 12 years

Male Gender

80.0% (82/103)

83.7% (60/72)

Hypertension

50.0% (51/103)

59.3% (42/72)

Hyperlipidemia

42.0%(43/103)

26.7% (19/72)

Diabetes mellitus

57.0% (58/103)

69.8% (50/72)

AV Fistulas mean age

25 months

22 months

Stenosis type:

   

de-novo

100%  (103/103)

100% (72/72)

outflow lesions

100.0% (103/103)

100.0% (72/72)

First treatment’s Tech Success

100.0% (103/103)

100,0% (72/72)

First treatment’s Clinical Success

100.0% (103/103)

100.0% (72/72)

Abbreviations: VEN+ANAST: Venous+Anastomosis; PTA: Percutaneous Transluminal Angioplasty; Nr: Number

Main objective of our study was to evaluate the Surviving Time in the two groups to estimate the effectiveness of PTA of the whole juxta-anastomotic region compared to PTA of the venous side of juxta-anastomotic region.

Surviving Time was defined in accord with the Kidney Disease Out-comes Quality Initiative recommendations as absence of dysfunction of the vascular access, patent lesion or residual stenosis <30% and no need for further intervention of the target lesion (TLR). Primary patency (PP) after PTA was evaluated with ECD at 6 and 12 months for both groups. Data were statistically analysed: the Survival Curves was estimated using Kaplan-Meyer analysis and compared with Logrank test.

RESULTS

First treatment technical and clinical successes were 100% for all the patients in both groups.

Technical success after PTA was defined as the reactivation of “thrill” and residual stenosis <30%; clinical success after PTA was defined as the ability to perform a regular dialysis immediately after the treatment. The ECD controls at 6 and 12 months showed respectively 100 and 82 patent AVFs in the group 1 and 57 and 39 patent AVFs in the group 2; so the 6 and 12 months Primary Patency rates were respectively 97% (100/103) and 79.6% (82/103) in the group 1 and 79.8% (57/72) and 54.1% (39/72) in the group 2 (table 2).

Table 2: Results.

Group

6 Months PP

12 Months PP

1

97% (100/103)

79.8% (57/72)

2

79.6% (82/103)

54.1% (39/72)

Group 1 shows higher Primary Patencies at 6 and 12 months

Abbreviations: PP: Primary Patency

Surviving Times were evaluated in the two groups, defined as absence of dysfunction of the vascular access, in accord with the Kidney Disease Out-comes Quality Initiative recommendations, patent lesion or residual stenosis <30% and no need for further reintervention of the target lesion [9]. As we can see in table 3,

Table 3: Results.

Factor

Mean Survival

SE

95% CI for the mean

0

359,612

3,141

353,455 to 365,768

1

326,458

8,992

308,835 to 344,082

Overall

345,971

4,288

337,567 to 354,376

Patients treated with venous and anastomosis’s PTA show higher mean survival rate and longer free period from TLR (Target Lesion Reintervention) compared to patients underwent only venous PTA.

Abbreviations: SE: Standard Error; CI: Confidence Interval

patients treated with venous and anastomotic PTA showed higher mean survival rate and longer free period from reintervention of the target lesion in comparison with patients who underwent only venous PTA with a statistically significant difference (P-value=0.0001) in Surviving Time evaluating the survival curves with the Logrank Test (Table 4).

Table 4: Results.

Comparison of survival curves (Logrank test)

Chi-squared

15,0968

DF

1

Significance

P=0,0001

Logrank test shows a statistically significant difference between the Survival Time of the two groups (P=0, 0001), higher in the group 1.

Abbreviations: DF: Degrees of Freedom

In fact the mean survival is 359 (SE: 3.141; 95% CI for the mean: 353. 455 to 365.768) in the group 1 and 326 (SE: 8.992; 95% CI for the mean: 308.835 to 344.082) in the group 2. The KaplanMeyer analysis (Figure 2)

Figure 2 Results: Kaplan-Meyer analysis shows a wide gap between  the two survival curves with a statistically significant difference.

Figure 2: Results: Kaplan-Meyer analysis shows a wide gap between the two survival curves with a statistically significant difference.

showed a wide gap between the two survival curves highlighting the group 1’s statistically significant higher Survival likelihood.

DISCUSSION

Balloon angioplasty continues to be the most accepted and cost-sensitive method of treating failing hemodialytic access [10]. Since the early reports of success, angioplasty has become the standard treatment for stenosis in both fistulas and grafts. The technique has been shown to be safe, easily performed and effective[11] and it is the first treatment option in the internationalguidelines [12]. Numerous studies describe the technique used, but the PTA’s outcomes were never evaluated in relation with the site of the balloon’s inflation. DK Rajan reviewed the use and outcome of PTA technologies, past, present and future as well as some of the questions that remain unanswered with PTA [10]; he analyzed the outcomes of many studies that evaluated factors that can affect the patency: the location of stenosis, the use of different devices as standard PTA balloons, cutting balloons, cryoplasty, paclitaxel-coated balloons (PCB) and stent graft placement. He evaluated also the choice of the balloon and the relationship between patency and inflation time concluding that the different inflation times (range: 1-5 min) did not affect access patency. Some authors evaluated the use of PCB in patients undergoing transluminal angioplasty for recurrent juxta-anastomotic stenosis of radio-cephalic AVF [13]. Their sample was similar to ours concerning site of AVF and stenosis and like us they used preferably transvenous approach and, only in patients who required, the transradial access, but the exact inflation site has not been reported and their PP rates were lower than ours. Others evaluated the efficacy and outcomes of 3 different percutaneous transluminal angioplasty approaches (transarterial, transvenous and combination) [14] but the site of inflation is not clear. In some studies evaluating predictors of technical success and patency after PTA of de novo dysfunctional hemodialysis AVF [15], they obtained the access to fistula through a brachial artery puncture. Some authors reported the technical success and long term clinical outcomes of immature AVF after PTA [16], for obliterated lesions: after initial constant failure of transvenous approach in their early patients, they routinely changed to transradial artery approach for later cases; occasionally they combined transvenous and transradial artery approach were necessary to successfully recanalize a tightly obliterated or ruptured venous segment of the venous outflow. We believe the venous retrograde approach is safer and allows the use of larger introducer sheaths with less risk than arterial antegrade access. Only when we are not able to cross the lesion or the anastomosis from the venous access we perform the transarterial antegrade approach but, in most of cases, just to cross the lesions and anastomosis, the guidewire is in fact antegradely advanced in the venous outflow, pulled back inside the introducer sheath previously placed in the venous retrograde access, snared and recovered from this site and the treatment is performed from the venous approach

Our results show a higher survival rate and longer free period from reintervention of target lesion in patients of the group 1, treated with PTA of the whole juxta-anastomotic region, in “V configuration”, in comparison with patients of the group 2, who underwent PTA of the simple venous side of the juxta-anastomotic region, in “V2 or Z configuration” with a statistically significant difference (P-value=0.0001) in Surviving Time. As we wrote before, there was not any dynamically significant anastomotic stenosis, as requested in the eligibility criteria. Some authors divide juxta-anastomotic region into three compartments, venous, arterial and anastomosis [9,17] and they perform PTA with the guidewire placed into the distal radial artery for dilation of purely venous stenosis and guidewire advanced into the proximal radial artery for dilation of stenosis located at the anastomosis itself or on the proximal artery [7]. We think that the juxta-anastomotic area, the region within 3 cm of the arteriovenous anastomosis [7], has to be considered a single compartment to be treated in its entirety, with angioplasty to be always performed crossing the anastomosis with the guidewire and inflation of balloon in “V shape configuration”. We believe in fact that anastomosis is always involved in the dysfunctional dialytic access due to juxta-anastomotic stenosis also without or not so obvious ECD appearance. Sometimes, for example, too angled anastomosis can create turbulence leading to stenosis, PTA in this site can help improve the anatomy of arteriovenous anastomosis, also when a hemodynamically significant stenosis is still not clearly evident at ECD. Furthermore, an angioplasty performed just in the venous juxta-anastomotic site cannot ensure the treatment of the entire stenotic lesion. For these reasons, supported by our results, in our standard practice, we always use thin materials, we perform as first choice the transvenous retrograde us-guided access and we always use “V shape” inflation to treat the stenosis of the juxtaanastomotic region either in presence or not of hemodynamically significant stenosis in every compartment of the region. Although drug eluting balloons (DEB) were never used in any patients of this study, in the last years we always used them, so once a good morphological result is achieved with standard balloons we always complete the treatment with the inflation of a DEB 0.5 mm bigger than the last standard balloon used. Indeed, as shown in literature, patients treated with standard PTA and DEB have higher primary and secondary patency rates compared to patients treated just with standard PTA [18,19].

Some authors consider the surgical creation of a new and slightly more proximal anastomosis as the preferred option in the management of juxta-anastomotic stenosis in forearm (18) and proposed surgery as the preferred treatment over the percutaneous approach for its better primary patency compared to PTA [7,17,21-26]. We believe the multiple confounders in these reports do not allow a good evaluation of patency rates: most of these works have not studied a homogeneous sample for type of AVF and site of stenosis and a small number of patients with juxta-anastomotic lesions were evaluated. In addition, most of the times they did not use thin material (0.014”, 0.018”) and PTA was performed without cross of anastomosis and the use of “V shape configuration”, as we described. In this work, we think our homogeneous sample, only consisting of patients with venous juxta-anastomotic stenosis and distal radio-cephalic AVFs, gave us an objective evaluation of primary patency and survival rates.

We believe the technical tips we described in this study can really affect PTA outcomes of the juxta-anastomotic stenosis of distal radio-cephalic fistulas, in fact our primary patency rates are higher than the results showed from other authors, with promising higher 6 and 12 months PP than the literature [2,6,7,20-28]. So we think that PTA performed in this way has to be considered the golden standard and first choice treatment in malfunctioning arteriovenous access, especially to preserve all the way distal radio-cephalic AVF and that the surgical proximalization has to be reserved only to patients who cannot be treated with endovascular approach.

The use of this technique seems to be effective and to improve primary and secondary patency and decrease reinterventions of target lesion in juxta-anastomotic stenoses of failing distal radiocephalic arteriovenous shunts with a statistically significant difference between the two groups examined and could make present and future technologies and devices more effective.

REFERENCES
  1. US Renal Data System. USRDS 2010 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States, National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, Chronic kidney disease in the general population. 2010.
  2. Clark TW, Hirsch DA, Jindal KJ, Veugelers PJ, LeBlanc J. Outcome and prognostic factors of restenosis after percutaneous treatment of native hemodialysis fistulas. J Vasc Interv Radiol. 2002; 13: 51-59.
  3. Bittl JA. Catheter interventions for hemodialysis fistulas and grafts. JACC Cardiovasc Interv. 2010; 3: 1-11.
  4. Beathard GA, Arnold P, Jackson J, Litchfield T. Physician Operators Forum of RMS Lifeline. Aggressive treatment of early fistula failure. Kidney Int. 2003; 64: 1487-1494.
  5. Rajan DK, Bunston S, Misra S, Pinto R, Lok CE. Dysfunctional autogenous hemodialysis fistulas: outcomes after angioplasty-are there clinical predictors of patency? Radiology. 2004; 232: 508-515.
  6. Asif A, Gadalean FN, Merrill D, Cherla G, Cipleu CD, Epstein DL, et al. Inflow stenosis in arteriovenous fistulas and grafts: a multicenter, prospective study. Kidney Int. 2005; 67: 1986-92.
  7. Long B, Brichart N, Lermusiaux P, Turmel-Rodrigues L, Artru B, Boutin JM, et al. Management of perianastomotic stenosis of direct wrist autogenous radial-cephalic arteriovenous accesses for dialysis. J Vasc Surg. 2011; 53: 108-114.
  8. Portugaller RH, Kalmar PI, Deutschmann H. The eternal tale of dialysis access vessels and restenosis: are drug-eluting balloons the solution? J Vasc Access. 2014; 15: 439-447.
  9. National Kidney Foundation K/DOQI clinical practice guidelines for vascular access. 2006.
  10. Rajan DK. Balloon angioplasty for low-flow access. J Vasc Access. 2015; 16: S66-67.
  11. Beathard GA. Percutaneous transvenous angioplasty in the treatment of vascular access stenosis. Kidney Int. 1992; 42: 1390-1397.
  12. Tordoir J, Canaud B, Haage P, Konner K, Basci A, Fouque D, et al. EBPG on Vascular Access. Nephrol Dial Transplant. 2007; 22: 88-117.
  13. Lai CC, Fang HC, Tseng CJ, Liu CP, Mar GY. Percutaneous angioplasty using a paclitaxel-coated balloon improves target lesion restenosis on inflow lesions of autogenousradiocephalic fistulas: a pilot study. J Vasc Interv Radiol. 2014; 25: 535-541.
  14. Ming Z, Li W, Ding W, Yuan R, Li X. The efficacy of percutaneous transluminal angioplasty treatment for the patients with arteriovenous fistula dysfunction. Int Angiol. 2016; 35: 163-169.
  15. Aktas A, Bozkurt A, Aktas B, Kirbas I. Percutaneous transluminal balloon angioplasty in stenosis of native hemodialysis arteriovenous fistulas: technical success and analysis of factors affecting postprocedural fistula patency. Diagn Interv Radiol. 2015; 21: 160-166.
  16. Liang HL, Fu JH, Wang PC, Chen MC, Wang CC, Lin YH, et al. Endovascular salvage of immature autogenous hemodialysis fistulas. Cardiovasc Intervent Radiol. 2014; 37: 671-678.
  17. Asif A, Lenz O, Merrill D, Cherla G, Cipleu CD, Ellis R, et al. Percutaneous management of perianastomotic stenosis in arteriovenous fistulae: results of a prospective study. Kidney Int. 2006; 69: 1904-1909.
  18. Patanè D, Giuffrida S, Morale W, L'Anfusa G, Puliatti D, Bisceglie P, et al. Drug-eluting balloon for the treatment of failing hemodialytic radiocephalic arteriovenous fistulas: our experience in the treatment of juxta-anastomotic stenoses. J Vasc Access. 2014; 15: 338-343.
  19. Giuffrida S, Bisceglie P, Morale W, Malfa P, Calcara G, Seminara G, et al. Il pallone medicato nel trattamento delle stenosi juxta-anastomotiche emodialitiche di fistole radio-cefaliche distali. Il giornaleitaliano di Radiologia Medica. 2016; 3: 106-112.
  20. Mortamais J, Papillard M, Girouin N, Boutier R, Cougnaud L, Martin X, et al. Endovascular treatment of juxta-anastomotic venous stenoses of forearm radiocephalic fistulas: long-term results and prognostic factors. J Vasc Interv Radiol. 2013; 24: 558-564.
  21. Kwok TM, Ramanathan AK. Fistuloplasty techniques for correction of juxta-anastomotic stenosis. Ann R Coll Surg Engl. 2014; 96: 480-481.
  22. Tessitore N, Mansueto G, Lipari G, Bedogna V, Tardivo S, Baggio E, et al. Endovascular versus surgical preemptive repair of forearm arteriovenous fistula juxta-anastomotic stenosis: analysis of data collected prospectively from 1999 to 2004. Clin J Am Soc Nephrol. 2006; 1: 448-454.
  23. Jiménez-Almonacid P, Gruss-Vergara E, Jiménez-Toscano M, Lasala M, Rueda JA, Portolés J, et al. Surgical treatment of juxta-anastomotic stenosis in radiocephalic fistula. A new proximal radiocephalic anastomosis. Nefrologia. 2012; 32: 517-522.
  24. Napoli M, Prudenzano R, Russo F, Antonaci AL, Aprile M, Buongiorno E. Juxta-anastomotic stenosis of native arteriovenous fistulas: surgical treatment versus percutaneous transluminal angioplasty. J Vasc Access. 2010; 11: 346-351.
  25. Argyriou C, Schoretsanitis N, Georgakarakos EI, Georgiadis GS, Lazarides MK. Preemptive open surgical vs. endovascular repair for juxta-anastomotic stenoses of autogenous AV fistulae: a meta-analysis. J Vasc Access. 2015; 16: 454-458.
  26. Kwon H, Choi JY, Ko HK, Kim MJ, Kim H, Park H, et al. Comparison of surgical and endovascular salvage procedures for juxta-anastomotic stenosis in autogenous wrist radiocephalic arteriovenous fistula. Ann Vasc Surg. 2014; 28: 1840-1846.
  27. Kim WS, Pyun WB, Kang BC. The primary patency of percutaneous transluminal angioplasty in hemodialysis patients with vascular access failure. Korean Circ J. 2011; 41: 512-517.
  28. Mantha M, Killen JP, Baer R, Moffat J. Percutaneous maintenance and salvage of dysfunctional arteriovenous fistulae and grafts by nephrologists in Australia. Nephrology (Carlton). 2011; 16: 46-52.

Giuffrida S, Bisceglie P, Morale W, Malfa P, Calcara G, et al. (2017) Percutaneous Angioplasty of Juxta-Anastomotic Stenosis of Failing Distal Radio-Cephalic Hemodialytic Arteriovenous Fistulas: Our Techniques in Comparison, an Attempt to Standardize the “Optimal Technique”. Ann Vasc Med Res 4(1): 1048.

 

Received : 14 Dec 2016
Accepted : 29 Mar 2017
Published : 31 Mar 2017
Journals
Annals of Otolaryngology and Rhinology
ISSN : 2379-948X
Launched : 2014
JSM Schizophrenia
Launched : 2016
Journal of Nausea
Launched : 2020
JSM Internal Medicine
Launched : 2016
JSM Hepatitis
Launched : 2016
JSM Oro Facial Surgeries
ISSN : 2578-3211
Launched : 2016
Journal of Human Nutrition and Food Science
ISSN : 2333-6706
Launched : 2013
JSM Regenerative Medicine and Bioengineering
ISSN : 2379-0490
Launched : 2013
JSM Spine
ISSN : 2578-3181
Launched : 2016
Archives of Palliative Care
ISSN : 2573-1165
Launched : 2016
JSM Nutritional Disorders
ISSN : 2578-3203
Launched : 2017
Annals of Neurodegenerative Disorders
ISSN : 2476-2032
Launched : 2016
Journal of Fever
ISSN : 2641-7782
Launched : 2017
JSM Bone Marrow Research
ISSN : 2578-3351
Launched : 2016
JSM Mathematics and Statistics
ISSN : 2578-3173
Launched : 2014
Journal of Autoimmunity and Research
ISSN : 2573-1173
Launched : 2014
JSM Arthritis
ISSN : 2475-9155
Launched : 2016
JSM Head and Neck Cancer-Cases and Reviews
ISSN : 2573-1610
Launched : 2016
JSM General Surgery Cases and Images
ISSN : 2573-1564
Launched : 2016
JSM Anatomy and Physiology
ISSN : 2573-1262
Launched : 2016
JSM Dental Surgery
ISSN : 2573-1548
Launched : 2016
Annals of Emergency Surgery
ISSN : 2573-1017
Launched : 2016
Annals of Mens Health and Wellness
ISSN : 2641-7707
Launched : 2017
Journal of Preventive Medicine and Health Care
ISSN : 2576-0084
Launched : 2018
Journal of Chronic Diseases and Management
ISSN : 2573-1300
Launched : 2016
Annals of Vaccines and Immunization
ISSN : 2378-9379
Launched : 2014
JSM Heart Surgery Cases and Images
ISSN : 2578-3157
Launched : 2016
Annals of Reproductive Medicine and Treatment
ISSN : 2573-1092
Launched : 2016
JSM Brain Science
ISSN : 2573-1289
Launched : 2016
JSM Biomarkers
ISSN : 2578-3815
Launched : 2014
JSM Biology
ISSN : 2475-9392
Launched : 2016
Archives of Stem Cell and Research
ISSN : 2578-3580
Launched : 2014
Annals of Clinical and Medical Microbiology
ISSN : 2578-3629
Launched : 2014
JSM Pediatric Surgery
ISSN : 2578-3149
Launched : 2017
Journal of Memory Disorder and Rehabilitation
ISSN : 2578-319X
Launched : 2016
JSM Tropical Medicine and Research
ISSN : 2578-3165
Launched : 2016
JSM Head and Face Medicine
ISSN : 2578-3793
Launched : 2016
JSM Cardiothoracic Surgery
ISSN : 2573-1297
Launched : 2016
JSM Bone and Joint Diseases
ISSN : 2578-3351
Launched : 2017
JSM Bioavailability and Bioequivalence
ISSN : 2641-7812
Launched : 2017
JSM Atherosclerosis
ISSN : 2573-1270
Launched : 2016
Journal of Genitourinary Disorders
ISSN : 2641-7790
Launched : 2017
Journal of Fractures and Sprains
ISSN : 2578-3831
Launched : 2016
Journal of Autism and Epilepsy
ISSN : 2641-7774
Launched : 2016
Annals of Marine Biology and Research
ISSN : 2573-105X
Launched : 2014
JSM Health Education & Primary Health Care
ISSN : 2578-3777
Launched : 2016
JSM Communication Disorders
ISSN : 2578-3807
Launched : 2016
Annals of Musculoskeletal Disorders
ISSN : 2578-3599
Launched : 2016
Annals of Virology and Research
ISSN : 2573-1122
Launched : 2014
JSM Renal Medicine
ISSN : 2573-1637
Launched : 2016
Journal of Muscle Health
ISSN : 2578-3823
Launched : 2016
JSM Genetics and Genomics
ISSN : 2334-1823
Launched : 2013
JSM Anxiety and Depression
ISSN : 2475-9139
Launched : 2016
Clinical Journal of Heart Diseases
ISSN : 2641-7766
Launched : 2016
Annals of Medicinal Chemistry and Research
ISSN : 2378-9336
Launched : 2014
JSM Pain and Management
ISSN : 2578-3378
Launched : 2016
JSM Women's Health
ISSN : 2578-3696
Launched : 2016
Clinical Research in HIV or AIDS
ISSN : 2374-0094
Launched : 2013
Journal of Endocrinology, Diabetes and Obesity
ISSN : 2333-6692
Launched : 2013
Journal of Substance Abuse and Alcoholism
ISSN : 2373-9363
Launched : 2013
JSM Neurosurgery and Spine
ISSN : 2373-9479
Launched : 2013
Journal of Liver and Clinical Research
ISSN : 2379-0830
Launched : 2014
Journal of Drug Design and Research
ISSN : 2379-089X
Launched : 2014
JSM Clinical Oncology and Research
ISSN : 2373-938X
Launched : 2013
JSM Bioinformatics, Genomics and Proteomics
ISSN : 2576-1102
Launched : 2014
JSM Chemistry
ISSN : 2334-1831
Launched : 2013
Journal of Trauma and Care
ISSN : 2573-1246
Launched : 2014
JSM Surgical Oncology and Research
ISSN : 2578-3688
Launched : 2016
Annals of Food Processing and Preservation
ISSN : 2573-1033
Launched : 2016
Journal of Radiology and Radiation Therapy
ISSN : 2333-7095
Launched : 2013
JSM Physical Medicine and Rehabilitation
ISSN : 2578-3572
Launched : 2016
Annals of Clinical Pathology
ISSN : 2373-9282
Launched : 2013
Annals of Cardiovascular Diseases
ISSN : 2641-7731
Launched : 2016
Journal of Behavior
ISSN : 2576-0076
Launched : 2016
Annals of Clinical and Experimental Metabolism
ISSN : 2572-2492
Launched : 2016
Clinical Research in Infectious Diseases
ISSN : 2379-0636
Launched : 2013
JSM Microbiology
ISSN : 2333-6455
Launched : 2013
Journal of Urology and Research
ISSN : 2379-951X
Launched : 2014
Journal of Family Medicine and Community Health
ISSN : 2379-0547
Launched : 2013
Annals of Pregnancy and Care
ISSN : 2578-336X
Launched : 2017
JSM Cell and Developmental Biology
ISSN : 2379-061X
Launched : 2013
Annals of Aquaculture and Research
ISSN : 2379-0881
Launched : 2014
Clinical Research in Pulmonology
ISSN : 2333-6625
Launched : 2013
Journal of Immunology and Clinical Research
ISSN : 2333-6714
Launched : 2013
Annals of Forensic Research and Analysis
ISSN : 2378-9476
Launched : 2014
JSM Biochemistry and Molecular Biology
ISSN : 2333-7109
Launched : 2013
Annals of Breast Cancer Research
ISSN : 2641-7685
Launched : 2016
Annals of Gerontology and Geriatric Research
ISSN : 2378-9409
Launched : 2014
Journal of Sleep Medicine and Disorders
ISSN : 2379-0822
Launched : 2014
JSM Burns and Trauma
ISSN : 2475-9406
Launched : 2016
Chemical Engineering and Process Techniques
ISSN : 2333-6633
Launched : 2013
Annals of Clinical Cytology and Pathology
ISSN : 2475-9430
Launched : 2014
JSM Allergy and Asthma
ISSN : 2573-1254
Launched : 2016
Journal of Neurological Disorders and Stroke
ISSN : 2334-2307
Launched : 2013
Annals of Sports Medicine and Research
ISSN : 2379-0571
Launched : 2014
JSM Sexual Medicine
ISSN : 2578-3718
Launched : 2016
JSM Biotechnology and Biomedical Engineering
ISSN : 2333-7117
Launched : 2013
Journal of Hematology and Transfusion
ISSN : 2333-6684
Launched : 2013
JSM Environmental Science and Ecology
ISSN : 2333-7141
Launched : 2013
Journal of Cardiology and Clinical Research
ISSN : 2333-6676
Launched : 2013
JSM Nanotechnology and Nanomedicine
ISSN : 2334-1815
Launched : 2013
Journal of Ear, Nose and Throat Disorders
ISSN : 2475-9473
Launched : 2016
JSM Ophthalmology
ISSN : 2333-6447
Launched : 2013
Journal of Pharmacology and Clinical Toxicology
ISSN : 2333-7079
Launched : 2013
Annals of Psychiatry and Mental Health
ISSN : 2374-0124
Launched : 2013
Medical Journal of Obstetrics and Gynecology
ISSN : 2333-6439
Launched : 2013
Annals of Pediatrics and Child Health
ISSN : 2373-9312
Launched : 2013
JSM Clinical Pharmaceutics
ISSN : 2379-9498
Launched : 2014
JSM Foot and Ankle
ISSN : 2475-9112
Launched : 2016
JSM Alzheimer's Disease and Related Dementia
ISSN : 2378-9565
Launched : 2014
Journal of Addiction Medicine and Therapy
ISSN : 2333-665X
Launched : 2013
Journal of Veterinary Medicine and Research
ISSN : 2378-931X
Launched : 2013
Annals of Public Health and Research
ISSN : 2378-9328
Launched : 2014
Annals of Orthopedics and Rheumatology
ISSN : 2373-9290
Launched : 2013
Journal of Clinical Nephrology and Research
ISSN : 2379-0652
Launched : 2014
Annals of Community Medicine and Practice
ISSN : 2475-9465
Launched : 2014
Annals of Biometrics and Biostatistics
ISSN : 2374-0116
Launched : 2013
JSM Clinical Case Reports
ISSN : 2373-9819
Launched : 2013
Journal of Cancer Biology and Research
ISSN : 2373-9436
Launched : 2013
Journal of Surgery and Transplantation Science
ISSN : 2379-0911
Launched : 2013
Journal of Dermatology and Clinical Research
ISSN : 2373-9371
Launched : 2013
JSM Gastroenterology and Hepatology
ISSN : 2373-9487
Launched : 2013
Annals of Nursing and Practice
ISSN : 2379-9501
Launched : 2014
JSM Dentistry
ISSN : 2333-7133
Launched : 2013
Author Information X